Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

  • ID: 4229094
  • Report
  • Region: Asia, Asia Pacific
  • 140 Pages
  • GBI Research
1 of 5
Rheumatoid Arthritis (RA) Market Forecast to Grow at a CAGR of 4.7%, from USD1.04 Billion in 2015 to USD1.44 Billion in 2022

FEATURED COMPANIES

  • AbbVie
  • Astellas
  • Bristol-Myers Squibb
  • Eli Lilly
  • Galapagos
  • Johnson & Johnson
  • MORE

Rheumatoid arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years (Lefèvre et al., 2009). Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability. RA can have a substantial impact on quality of life and place a considerable economic burden upon the patient.

The advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. The South-East Asia market, which for the purposes of this report comprises South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, is forecast to grow at a compound annual growth rate (CAGR) of 4.7%, from USD1.04 Billion in 2015 to USD1.44 Billion in 2022. South Korea accounted for most of the market in 2015 with a 29.9% share, followed by Malaysia with 19.0%, the Philippines with 14.2%, Vietnam with 9.4%, Taiwan with 8.5%, Indonesia with 7.1%, Singapore with 6.4%, and Thailand with 5.5%.

The entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Eli Lilly and Incyte’s baricitinib, Regeneron’s sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson’s sirukumab, Astellas’ peficitinib (ASP015K), and AbbVie’s upadacitinib. Galapagos’ filgotinib is in late-stage development, but it will not be launched during the forecast period, as its Phase III trial completion date is in Q3 2020.

The therapeutic market for RA has become extremely competitive owing to the number of new drug approvals. Competition for tumor necrosis factor alpha (TNF-a) inhibitors is particularly fierce and now dominates the treatment market for RA patients who are refractory to first-line DMARDs. In 2015, Humira (adalimumab), MabThera/Rituxan (rituximab) and Remicade (infliximab) were ranked among the top-10 best-selling drugs in the world, with global revenue of USD14.01 Billion, USD7.33 Billion and USD6.56 Billion, respectively, reflecting their groundbreaking clinical and commercial success.

The report ""Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs"" provides an introduction to rheumatoid arthritis (RA), covering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In addition, this report also provides the following analysis:

  • Provides an overview of the RA marketed products landscape, including product profiles of key marketed products and heat maps that compare the safety and efficacy parameters of the various drugs.
  • Analyzes the RA pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
  • Provides detailed analysis of recent clinical trials in RA by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the RA market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015-2022 period. The eight South-East Asia markets are covered and data are presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for RA in South-East Asia markets.

Companies mentioned in this report: Eli Lilly and Incyte’s baricitinib, Regeneron’s sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson’s sirukumab, Astellas’ peficitinib (ASP015K), and AbbVie’s upadacitinib, Galapagos’ filgotinib.

Scope

  • The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.
  • What are the competitive advantages of the existing novel drugs?
  • There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
  • Which classes of novel drugs are most prominent in the pipeline?
  • What is the potential for pipeline products to address unmet needs in the RA market?
  • Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.
  • How do failure rates vary by stage of development, molecule type, and molecular target?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
  • Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
  • Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
  • Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

This report will enable you to:

  • Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
  • Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
  • Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Astellas
  • Bristol-Myers Squibb
  • Eli Lilly
  • Galapagos
  • Johnson & Johnson
  • MORE

1 Introduction

2. Disease Introduction
2.1 Epidemiology
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.4 Diagnosis
2.4.1 Physical Examination
2.4.2 Blood Tests
2.4.3 1987 Rheumatoid Arthritis Classification
2.4.4 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
2.5 Prognosis
2.6 Treatment Guidelines and Options
2.6.1 Pharmacological
2.6.2 Methotrexate
2.6.3 Hydroxychloroquine
2.6.4 Leflunomide
2.6.5 Sulfasalazine
2.6.6 Cyclosporine
2.6.7 Xeljanz (tofacitinib)
2.6.8 Other Non-biologics
2.6.9 Biologic Disease-Modifying Anti-rheumatic Drugs
2.6.10 Disease Scoring Methods for Measuring Treatment Efficacy
2.7 Co-infection or Co-morbidities

3 Marketed Products
3.1 Overview
3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs
3.2.1 Methotrexate-Based Products
3.2.2 Xeljanz (tofacitinib) - Pfizer
3.3 Biologic Disease-Modifying Anti-rheumatic Drugs
3.3.1 Infliximab
3.3.2 Humira (adalimumab) - AbbVie
3.3.3 Etanercept
3.3.4 Rituximab
3.3.5 Orencia (abatacept) - Bristol-Myers Squibb
3.3.6 Simponi (golimumab) - Johnson & Johnson, Merck
3.3.7 Cimzia (certolizumab pegol) - UCB
3.3.8 Actemra (tocilizumab) - Roche
3.4 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Baricitinib - Eli Lilly
4.4.2 Sarilumab - Regeneron/Sanofi
4.4.3 Sirukumab - Johnson & Johnson
4.4.4 Peficitinib - Astellas
4.4.5 Upadacitinib - AbbVie
4.4.6 Filgotinib - Galapagos
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
5.2.1 Trial Duration by Stage of Development and Molecule Type
5.2.2 Trial Duration by Stage of Development and Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Product by Stage of Development and Molecule Type/Molecular Target
5.3.2 Patient Enrollment per Trial by Stage of Development and Molecule Type/Molecular Target
5.4 Summary of Clinical Trial Metrics

6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 South-East Asia Markets
6.3 South Korea
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 Singapore
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Taiwan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Malaysia
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Philippines
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
6.8 Thailand
6.8.1 Treatment Usage Patterns
6.8.2 Annual Cost of Therapy
6.8.3 Market Size
6.9 Vietnam
6.9.1 Treatment Usage Patterns
6.9.2 Annual Cost of Therapy
6.9.3 Market Size
6.10 Indonesia
6.10.1 Treatment Usage Patterns
6.10.2 Annual Cost of Therapy
6.10.3 Market Size
6.11 Market Dynamics (Drivers and Barriers)
6.11.1 Drivers
6.11.2 Barriers

7 Deals and Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region and Value
7.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
7.1.4 Mylan Enters into Licensing Agreement with Momenta Pharmaceuticals for Biosimilar Candidates
7.1.5 Roche Enters into Licensing Agreement with Proximagen for VAP-1 Inhibitor
7.1.6 Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb and Alder Biopharmaceuticals for Clazakizumab
7.1.7 Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-0061
7.2 Co-development
7.2.1 Deals by Region and Value
7.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
7.2.4 Gilead Sciences Enters into Co-development Agreement with Galapagos
7.2.5 Nextera Enters into Research Agreement with Janssen Biotech
7.2.6 GlaxoSmithKline Enters into Global Agreement with Archemix
7.2.7 Chroma Therapeutics Enters into Co-development Agreement with GlaxoSmithKline

8 Appendix
8.1 All Pipeline Drugs by Stage of Development
8.1.1 Discovery
8.1.2 Preclinical
8.1.3 IND/CTA-filed
8.1.4 Phase I
8.1.5 Phase II
8.1.6 Phase III
8.1.7 Pre-registration
8.2 Summary of Multi-Scenario Market Forecasts to 2022
8.3 Abbreviations
8.4 References
8.5 Research Methodology
8.5.1 Secondary Research
8.5.2 Marketed Product Profiles
8.5.3 Late-Stage Pipeline Candidates
8.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
8.5.5 Pipeline Analysis
8.5.6 Forecasting Model
8.5.7 Deals Data Analysis

List of Tables

Table 1: RA Therapeutics Market, South-East Asia, Prevalence rate (%), 2015
Table 2: ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010
Table 3: RA Therapeutics Market, Global, Licensing Deals Valued over $10m, 2006-2016
Table 4: RA Therapeutics Market, Global, Co-development Deals Valued over $10m, 2006-2016
Table 5: RA Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 6: RA Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 7: RA Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016
Table 8: RA Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 9: RA Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 10: RA Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 11: RA Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
Table 12: RA Therapeutics Market, South-East Asia, Market Forecast, 2015-2022
Table 13: RA Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 14: RA Therapeutics Market, Singapore, Market Forecast, 2015-2022
Table 15: RA Therapeutics Market, Taiwan, Market Forecast, 2015-2022
Table 16: RA Therapeutics Market, Malaysia, Market Forecast, 2015-2022
Table 17: RA Therapeutics Market, Philippines, Market Forecast, 2015-2022
Table 18: RA Therapeutics Market, Thailand, Market Forecast, 2015-2022
Table 19: RA Therapeutics Market, Vietnam, Market Forecast, 2015-2022
Table 20: RA Therapeutics Market, Indonesia, Market Forecast, 2015-2022

List of Figures

Figure 1: American College of Rheumatology Treatment Guidelines, 2012
Figure 2: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Synthetic Disease Modifying Anti-rheumatic Marketed Products
Figure 3: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for TNF-a Biologic Disease Modifying Anti-rheumatic Marketed Products
Figure 4: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Non TNF-a Biologic Disease Modifying Anti-rheumatic Marketed Products
Figure 5: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Targeted Synthetic Disease Modifying Anti-rheumatic Marketed Products
Figure 6: RA Therapeutics Market, Global, Pipeline, 2016
Figure 7 RA Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 8: RA Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 9: RA Therapeutics Market, South-East Asia, Baricitinib Forecast ($m), 2017-2022
Figure 10: RA Therapeutics Market, South-East Asia, Sarilumab Forecast ($m), 2018-2022
Figure 11: RA Therapeutics Market, South-East Asia, Sirukumab Forecast ($m), 2018-2022
Figure 12: RA Therapeutics Market, South-East Asia, Peficitinib Forecast ($m), 2020-2022
Figure 13: RA Therapeutics Market, South-East Asia, Upadacitinib Forecast ($m), 2020-2022
Figure 14: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
Figure 15: RA Therapeutics Market, Competitor Matrix for RA Marketed and Pipeline Products, 2016
Figure 16: RA Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2016
Figure 17: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2016
Figure 18: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006-2016
Figure 19: RA Therapeutics Market, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2016
Figure 20: RA Therapeutics Market, Global, Clinical Trial Duration by Molecular Target, 2006-2016
Figure 21: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type, 2006-2016
Figure 22: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2006-2016
Figure 23: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2016
Figure 24: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2016
Figure 25: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 26: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 27: RA Therapeutics Market, South-East Asia, Treatment Usage Patterns (million), 2015-2022
Figure 28: RA Therapeutics Market, South-East Asia, Market Size ($bn), 2015-2022
Figure 29: RA Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2015-2022
Figure 30: RA Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 31: RA Therapeutics Market, South Korea, Market Size ($m), 2015-2022
Figure 32: RA Therapeutics Market, Singapore, Treatment Usage Patterns (‘000), 2015-2022
Figure 33: RA Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2015-2022
Figure 34: RA Therapeutics Market, Singapore, Market Size ($m), 2015-2022
Figure 35: RA Therapeutics Market, Taiwan, Treatment Usage Patterns (‘000), 2015-2022
Figure 36: RA Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2015-2022
Figure 37: RA Therapeutics Market, Taiwan, Market Size ($m), 2015-2022
Figure 38: RA Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2015-2022
Figure 39: RA Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2015-2022
Figure 40: RA Therapeutics Market, Malaysia, Market Size ($m), 2015-2022
Figure 41: RA Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2015-2022
Figure 42: RA Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2015-2022
Figure 43: RA Therapeutics Market, Philippines, Market Size ($m), 2015-2022
Figure 44: RA Therapeutics Market, Thailand, Treatment Usage Patterns (‘000), 2015-2022
Figure 45: RA Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2015-2022
Figure 46: RA Therapeutics Market, Thailand, Market Size ($m), 2015-2022
Figure 47: RA Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2015-2022
Figure 48: RA Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2015-2022
Figure 49: RA Therapeutics Market, Vietnam, Market Size ($m), 2015-2022
Figure 50: RA Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2015-2022
Figure 51: RA Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2015-2022
Figure 52: RA Therapeutics Market, Indonesia, Market Size ($m), 2015-2022
Figure 53: RA Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 54: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 55: RA Therapeutics Market, Global, Licensing Deals by Stage of Development, and Deal Value, 2006-2016
Figure 56: RA Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 57: RA Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2016
Figure 58: RA Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016
Figure 59: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 60: RA Therapeutics Market, Global, Co-development Deals by Stage of Development, and Deal Value, 2006-2016
Figure 61: RA Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2016
Figure 62: Rheumatoid Arthritis Market, Global, Co-development Deals by Molecular Target, 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie
  • Astellas
  • Bristol-Myers Squibb
  • Eli Lilly
  • Galapagos
  • Johnson & Johnson
  • Johnson & Johnson, Merck
  • Pfizer
  • Regeneron/Sanofi
  • Roche
  • UCB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll